GlassScriptPhysician profile
Mohamed Eldokmak
NPI 1700405743
$1,923.68
in general payments reported to CMS, 2019-2025
25 companies · $1,924 in 2025
The $1,924 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2025: $1,924.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,924.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,923.68 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $251.49 | 2025 | Zilbrysq, Neupro, Briviact |
| Pfizer INC. | $224.94 | 2025 | |
| Eisai INC. | $177.40 | 2025 | |
| Abbvie INC. | $172.11 | 2025 | |
| Otsuka America Pharmaceutical, INC. | $144.88 | 2025 | Rexulti |
| Argenx US, INC. | $141.14 | 2025 | Vyvgart, Vyvgart Hytrulo |
| Medtronic, INC. | $129.01 | 2025 | Kyphon Express II Kyphopak Tray, Inceptiv |
| Sk Life Science, INC. | $81.81 | 2025 | Xcopri |
| Jazz Pharmaceuticals INC. | $77.59 | 2025 | |
| Lilly USA, LLC | $71.40 | 2025 | Kisunla |
| Novartis Pharmaceuticals Corporation | $64.04 | 2025 | |
| Alexion Pharmaceuticals, INC. | $55.79 | 2025 | Ultomiris |
| Ani Pharmaceuticals, INC. | $49.47 | 2025 | Purified Cortrophin Gel |
| Lundbeck LLC | $43.84 | 2025 | Vyepti |
| Csl Behring | $33.46 | 2025 | Hizentra |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Avadel Cns Pharmaceuticals, LLC | $30.95 | 2025 | Lumryz |
| Octapharma USA, INC. | $29.56 | 2025 | Panzyga |
| Takeda Pharmaceuticals U.S.A., INC. | $26.44 | 2025 | Hyqvia |
| C2n Diagnostics, LLC | $21.81 | 2025 | Precivityad2 |
| Emd Serono, INC. | $19.82 | 2025 | |
| Boston Scientific Corporation | $19.21 | 2025 | General - Therapies |
| Vanda Pharmaceuticals INC. | $19.05 | 2025 | Ponvory |
| Tg Therapeutics, INC. | $16.23 | 2025 | |
| Neurocrine Biosciences, INC. | $13.95 | 2025 | |
| Life Molecular Imaging LTD | $8.29 | 2025 | Neuraceq |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mohamed Eldokmak listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.